Rheumatoid cachexia and cardiovascular disease

Clinical and Experimental Rheumatology

Volumn 27, Issue 6, 2009, Pages 985-988

  Metsios, George S ^a,b,c   Stavropoulos Kalinoglou, Antonios ^a,b,c   Panoulas, Vasileios F ^b   Sandoo, Aamer ^b   Toms, Tracey E ^b   Nevill, Alan M ^a   Koutedakis, Yiannis ^a,c   Kitas, George D ^b  

^a UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^b RUSSELLS HALL HOSPITAL   (United Kingdom)

^c Center for Research and Technology   (Greece)

Author keywords

Body composition; Body mass index; Cardiovascular disease; Fat free mass; Medication; Morbidity; Mortality; Obesity; Prevalence; Rheumatoid arthritis; Rheumatoid cachexia

Indexed keywords

ALBUMIN; APOLIPOPROTEIN B; CHOLESTEROL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FIBRINOGEN; HEMOGLOBIN; HOMOCYSTEINE; LEFLUNOMIDE; LOW DENSITY LIPOPROTEIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLASMINOGEN ACTIVATOR INHIBITOR; PREDNISOLONE; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; URIC ACID; VON WILLEBRAND FACTOR;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BODY FAT; BODY MASS; CACHEXIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATABOLISM; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DATA BASE; DIASTOLIC BLOOD PRESSURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; INSULIN RESISTANCE; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOID CACHEXIA; SMOKING; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ARTHRITIS, RHEUMATOID; BODY MASS INDEX; CACHEXIA; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 76649137239     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. METSIOS GS, STAVROPOULOS-KALINGLOU A, PANOULAS VF, KOUTEDAKIS Y, KITAS GD: Metabolism in patients with rheumatoid arthritis: resting energy expenditure, physical activity and diet-induced thermogenesis. Invited review. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 2008; 2: 97-102.
2. METSIOS GS, STAVROPOULOS-KALINOGLOU A, PANOULAS VF et al.: New resting energy expenditure prediction equations for patients with rheumatoid arthritis. Rheumatology (Oxford) 2008; 47: 500-6.
3. ROUBENOFF R, ROUBENOFF RA, CANNON JG et al.: Rheumatoid cachexia: cytokinedriven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 1994; 93: 2379-86.
4. STAVROPOULOS-KALINOGLOU A, METSIOS GS, KOUTEDAKIS Y et al.: Redefining overweight and obesity in rheumatoid arthritis patients. Ann Rheum Dis 2007; 66: 1316-21.
5. MARCORA S, LEMMEY A, MADDISON P: Dietary treatment of rheumatoid cachexia with beta-hydroxy-beta-methylbutyrate, glutamine and arginine: a randomised controlled trial. Clin Nutr 2005; 24: 442-54.
6. MARCORA SM, LEMMEY AB, MADDISON PJ: Can progressive resistance training reverse cachexia in patients with rheumatoid arthritis? Results of a pilot study. J Rheumatol 2005; 32: 1031-9.
7. METSIOS GS, STAVROPOULOS-KALINOGLOU A, DOUGLAS KM et al.: Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia. Rheumatology (Oxford) 2007; 46: 1824-7.
8. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, BERJA A et al.: Anti-tumour necrosis factor alpha therapy modulates ghrelin in patients with severe rheumatoid arthritis. Ann Rheum Dis 2008; 67: 1644-6.
9. WALSMITH J ROUBENOFF R: Cachexia in rheumatoid arthritis. Int J Cardiol 2002; 85: 89-99.
10. PANOULAS VF, DOUGLAS KM, MILIONIS HJ et al.: Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 1477-82.
11. ENGVALL IL, ELKAN AC, TENGSTRAND B, CEDERHOLM T, BRISMAR K, HAFSTROM I: Cachexia in rheumatoid arthritis is associated with inflammatory activity, physical disability, and low bioavailable insulin-like growth factor. Scand J Rheumatol 2008; 37: 321-8.
12. SCHUTZ Y, KYLE UU, PICHARD C: Fat-free mass index and fat mass index percentiles in Caucasians aged 18-98 y. Int J Obes Relat Metab Disord 2002; 26: 953-60.
13. GONZALEZ-GAY MA, LLORCA J, GARCIA-UNZUETA MT et al.: High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 596-603.
14. ANTUNA-PUENTE B, FEVE B, FELLAHI S, BASTARD JP: Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008; 34: 2-11.
15. STAVROPOULOS-KALINOGLOU A, METSIOS GS, PANOULAS VF et al.: Associations of obesity with modifiable risk factors for the development of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis 2009; 68: 242-5.
16. MORLEY JE, THOMAS DR, WILSON MM: Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006; 83: 735-43.
17. STAVROPOULOS-KALINOGLOU A, METSIOS GS, PANOULAS VF et al.: Underweight and obese states both associate with worse disease activity and physical function in patients with established rheumatoid arthritis. Clin Rheumatol 2008;
18. SUMMERS GD, DEIGHTON CM, RENNIE MJ, BOOTH AH: Rheumatoid cachexia: a clinical perspective. Rheumatology (Oxford) 2008; 47: 1124-31.
19. HEITMANN BL, KONDRUP J, ENGELHART M et al.:Changes in fat free mass in overweight patients with rheumatoid arthritis on a weight reducing regimen. A comparison of eight different body composition methods. Int J Obes Relat Metab Disord 1994; 18: 812-9.